Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Classical Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05451810
What this trial is testing

Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaClassic Follicular Lymphoma
Genmab 184
Testing effectiveness (Phase 2)Study completedNCT02927769
What this trial is testing

Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Who this might be right for
Hodgkin Disease
Bristol-Myers Squibb 72
Testing effectiveness (Phase 2)Study completedNCT02164500
What this trial is testing

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Classical Hodgkin Lymphoma
University of Cologne 12
Early research (Phase 1)Active Not RecruitingNCT05352828
What this trial is testing

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Who this might be right for
Classical Hodgkin LymphomaHodgkin Disease RefractoryHodgkin Disease Recurrent
Tessa Therapeutics 15
Testing effectiveness (Phase 2)UnknownNCT03077828
What this trial is testing

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Lymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin Lymphoma+4 more
Northwestern University 43
Testing effectiveness (Phase 2)UnknownNCT03800706
What this trial is testing

A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Who this might be right for
Safety and Effectiveness
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 85
Testing effectiveness (Phase 2)Looking for participantsNCT05039073
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University 46
Testing effectiveness (Phase 2)Study completedNCT04875195
What this trial is testing

Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Who this might be right for
Hodgkin's LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)
Merck Sharp & Dohme LLC 66
Testing effectiveness (Phase 2)Study completedNCT04052997
What this trial is testing

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Relapsed Hodgkin LymphomaRefractory Hodgkin Lymphoma
ADC Therapeutics S.A. 117
Early research (Phase 1)Active Not RecruitingNCT04288726
What this trial is testing

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine 27
Not applicableStudy completedNCT03766516
What this trial is testing

Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL

Who this might be right for
Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
Samsung Medical Center 90
Early research (Phase 1)Study completedNCT02665650
What this trial is testing

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Affimed GmbH 30
Testing effectiveness (Phase 2)UnknownNCT05137886
What this trial is testing

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 47
Testing effectiveness (Phase 2)Study completedNCT03722147
What this trial is testing

Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

Who this might be right for
Hodgkin's Lymphoma
Akeso 94
Testing effectiveness (Phase 2)Active Not RecruitingNCT05821088
What this trial is testing

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD
Testing effectiveness (Phase 2)Study completedNCT03505996
What this trial is testing

CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
CStone Pharmaceuticals 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268706
What this trial is testing

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Who this might be right for
Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease Refractory+1 more
Tessa Therapeutics 97
Testing effectiveness (Phase 2)Looking for participantsNCT04838652
What this trial is testing

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
University of Cologne 29
Large-scale testing (Phase 3)UnknownNCT04342936
What this trial is testing

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
Jiangsu HengRui Medicine Co., Ltd. 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT01896999
What this trial is testing

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI) 146
Next Page
37